Influence of Janus kinase inhibitors on early postoperative complications in patients with rheumatoid arthritis undergoing orthopaedic surgeries

We retrospectively reviewed the records of rheumatoid arthritis (RA) patients who underwent orthopaedic surgery to examine the influence of the perioperative use of Janus kinase (JAK) inhibitors on early postoperative complications. Thirty-two patients with RA under disease control with JAK inhibito...

Full description

Saved in:
Bibliographic Details
Published in:Modern rheumatology 2024-03, Vol.34 (3), p.466-473
Main Authors: Nishida, Keiichiro, Harada, Ryozo, Nasu, Yoshihisa, Naniwa, Shuichi, Nakahara, Ryuichi, Hotta, Yoshifumi, Shimizu, Noriyuki, Lin, Deting, Ozaki, Toshifumi
Format: Article
Language:English
Subjects:
Antirheumatic Agents - adverse effects
Arthritis, Rheumatoid - complications
Arthritis, Rheumatoid - drug therapy
Arthritis, Rheumatoid - surgery
Humans
Janus Kinase Inhibitors - adverse effects
Orthopedic Procedures - adverse effects
Postoperative Complications - drug therapy
Retrospective Studies
Surgical Wound Infection - drug therapy
Surgical Wound Infection - etiology
Surgical Wound Infection - prevention & control
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We retrospectively reviewed the records of rheumatoid arthritis (RA) patients who underwent orthopaedic surgery to examine the influence of the perioperative use of Janus kinase (JAK) inhibitors on early postoperative complications. Thirty-two patients with RA under disease control with JAK inhibitors who underwent 49 orthopaedic procedures were included in the study. Patient records after surgery were investigated for surgical site infection (SSI), delayed wound healing (DWH), a flare-up of the disease, preoperative and postoperative absolute lymphocyte counts (ALCs), venous thromboembolism, and other postoperative complications. JAK inhibitors were continued during the perioperative period in 31 procedures. In the remaining 18 procedures, JAK inhibitors were discontinued perioperatively with a mean discontinuation period of 2.4 days. No instances of SSI were identified in any patient during at least 90 days' follow-up, while DWH was seen in one patient. Disease flare-up was noted in two patients after 3 and 9 days of discontinuation of JAK inhibitors, respectively. The ALCs significantly decreased on postoperative Day 1 (P 
ISSN:1439-7595
1439-7609
DOI:10.1093/mr/road047